CN103360393B - 茶碱乙酸的制备方法 - Google Patents
茶碱乙酸的制备方法 Download PDFInfo
- Publication number
- CN103360393B CN103360393B CN201310321329.3A CN201310321329A CN103360393B CN 103360393 B CN103360393 B CN 103360393B CN 201310321329 A CN201310321329 A CN 201310321329A CN 103360393 B CN103360393 B CN 103360393B
- Authority
- CN
- China
- Prior art keywords
- theophylline
- acetic acid
- sodium
- sodium salt
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 229950003769 acefylline Drugs 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 39
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- 239000000243 solution Substances 0.000 claims abstract description 26
- IHJVDPWMLXFQAI-UHFFFAOYSA-N 1,3-dimethyl-7h-purine-2,6-dione;sodium Chemical compound [Na].O=C1N(C)C(=O)N(C)C2=C1NC=N2 IHJVDPWMLXFQAI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000007864 aqueous solution Substances 0.000 claims abstract description 19
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000011734 sodium Substances 0.000 claims abstract description 6
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 6
- 238000004809 thin layer chromatography Methods 0.000 claims description 22
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 7
- 238000006482 condensation reaction Methods 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 6
- QHTPSODXPLCXJB-UHFFFAOYSA-N piperazine;urea Chemical compound NC(N)=O.C1CNCCN1 QHTPSODXPLCXJB-UHFFFAOYSA-N 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 239000012267 brine Substances 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 239000005864 Sulphur Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 238000009413 insulation Methods 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 abstract description 9
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 238000005352 clarification Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000003556 assay Methods 0.000 abstract description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 17
- 239000000047 product Substances 0.000 description 14
- 229960000278 theophylline Drugs 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 235000011054 acetic acid Nutrition 0.000 description 8
- -1 theophylline acetic acids Chemical class 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- HAAJFUJFGYCCPU-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid;piperazine Chemical compound C1CNCCN1.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HAAJFUJFGYCCPU-UHFFFAOYSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229960003113 acefylline piperazine Drugs 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- IBUNINKEDDWCKG-UHFFFAOYSA-N 7-[2-(dimethylamino)ethoxy]-2-phenylchromen-4-one;2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.C=1C(OCCN(C)C)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 IBUNINKEDDWCKG-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 0 CN(C(N1C)[U])C(N=CC2CC([*-])=O)=C2C1=O Chemical compound CN(C(N1C)[U])C(N=CC2CC([*-])=O)=C2C1=O 0.000 description 1
- IPUHJDQWESJTGD-PFWPSKEQSA-N Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O.Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 Chemical compound Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O.Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 IPUHJDQWESJTGD-PFWPSKEQSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229940113035 ambroxol-theophylline-7-acetate Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical class O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010137 moulding (plastic) Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- QVGLHVDBDYLFON-UHFFFAOYSA-M sodium;1,3-dimethylpurin-7-ide-2,6-dione Chemical compound [Na+].O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 QVGLHVDBDYLFON-UHFFFAOYSA-M 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310321329.3A CN103360393B (zh) | 2013-07-29 | 2013-07-29 | 茶碱乙酸的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310321329.3A CN103360393B (zh) | 2013-07-29 | 2013-07-29 | 茶碱乙酸的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103360393A CN103360393A (zh) | 2013-10-23 |
CN103360393B true CN103360393B (zh) | 2016-01-06 |
Family
ID=49362738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310321329.3A Active CN103360393B (zh) | 2013-07-29 | 2013-07-29 | 茶碱乙酸的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103360393B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3562273A (en) * | 1966-02-17 | 1971-02-09 | Ferrer Labor | Tris (hydroxymethyl) aminomethane theophylline acetate |
US6066641A (en) * | 1994-12-13 | 2000-05-23 | Euro-Celtique S.A. | Aryl thioxanthines |
WO2003024965A2 (en) * | 2001-09-19 | 2003-03-27 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
CN101384261A (zh) * | 2005-12-22 | 2009-03-11 | 海德拉生物科学公司 | 治疗疼痛的方法和组合物 |
CN101407517A (zh) * | 2008-11-26 | 2009-04-15 | 成都摩尔生物医药有限公司 | 氨溴索茶碱-7-乙酸盐的制备方法 |
WO2011156632A2 (en) * | 2010-06-09 | 2011-12-15 | Georgetown University | Compositions and methods of treatment for tumors in the nervous system |
CN102796102A (zh) * | 2012-06-13 | 2012-11-28 | 广州万孚生物技术股份有限公司 | 咖啡因半抗原、偶联物及应用、咖啡因检测或测定方法 |
-
2013
- 2013-07-29 CN CN201310321329.3A patent/CN103360393B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3562273A (en) * | 1966-02-17 | 1971-02-09 | Ferrer Labor | Tris (hydroxymethyl) aminomethane theophylline acetate |
US6066641A (en) * | 1994-12-13 | 2000-05-23 | Euro-Celtique S.A. | Aryl thioxanthines |
WO2003024965A2 (en) * | 2001-09-19 | 2003-03-27 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
CN101384261A (zh) * | 2005-12-22 | 2009-03-11 | 海德拉生物科学公司 | 治疗疼痛的方法和组合物 |
CN101407517A (zh) * | 2008-11-26 | 2009-04-15 | 成都摩尔生物医药有限公司 | 氨溴索茶碱-7-乙酸盐的制备方法 |
WO2011156632A2 (en) * | 2010-06-09 | 2011-12-15 | Georgetown University | Compositions and methods of treatment for tumors in the nervous system |
CN102796102A (zh) * | 2012-06-13 | 2012-11-28 | 广州万孚生物技术股份有限公司 | 咖啡因半抗原、偶联物及应用、咖啡因检测或测定方法 |
Non-Patent Citations (3)
Title |
---|
Effects of Alkyl Substitutions of Xanthine Skeleton on Bronchodilation;Ryosuke Sakai 等;《J. Med. Chem.》;19921130;第35卷(第22期);第4039-4044页 * |
New Syntheses of Caffeine and Theophylline;BOGUSLAW BOBRANSKI 等;《Journal of the American Pharmaceutical Association》;19481231;第37卷(第2期);第62-62页,尤其第64页右栏第2段 * |
茶胺黄酮的合成;夏莘强;《中国医药工业杂志》;19771031(第10期);第37-38页,尤其第38页操作方法中7-乙酸茶碱的制备 * |
Also Published As
Publication number | Publication date |
---|---|
CN103360393A (zh) | 2013-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104829523B (zh) | 瑞戈非尼盐及其晶型、制备方法 | |
CN103664912B (zh) | 一种普卡必利的合成工艺 | |
CN102432548A (zh) | 合成苯氧基二氨基嘧啶衍生物的方法 | |
CN103601686A (zh) | 一锅法合成含氟的嘧啶类化合物的方法 | |
CN101475476A (zh) | 一种吉法酯化合物及其合成方法 | |
CN103360393B (zh) | 茶碱乙酸的制备方法 | |
CN101302207B (zh) | 3-ο-烷基-5,6-ο-(1-甲基乙叉基)-l-抗坏血酸的制造方法以及5,6-ο-(1-甲基乙叉基)-l-抗坏血酸的制造方法 | |
EP2669293B1 (en) | Preparation method of rocuronium | |
CN105384686B (zh) | 一种博舒替尼结晶方法 | |
CN102093263B (zh) | 一种氯吡格雷拆分剂左旋樟脑磺酸的回收方法 | |
CN107235921B (zh) | 一种埃罗替尼的制备方法 | |
CN102924295B (zh) | 一种盐酸溴己新晶体及其制备方法和用途 | |
CN101565428B (zh) | 普卢利沙星的制备方法 | |
CN101555204B (zh) | 一种咖啡酸原料药的制备方法 | |
CN110981816B (zh) | 一种4-氨基-2.6-二甲氧基嘧啶的合成方法 | |
CN108997209B (zh) | 一种瑞戈非尼的制备方法 | |
CN102924436A (zh) | 一种盐酸法舒地尔的精制方法 | |
CN106478524A (zh) | 一种盐酸氨溴索杂质标准品的制备方法 | |
CN104761599A (zh) | 一种5,4’-二羟基黄酮-7-o-d-葡萄糖醛酸的制备方法 | |
CN105294620A (zh) | 4-氨基-5-氯-2,3-二氢-7-苯并呋喃甲酸的合成方法 | |
CN102924417A (zh) | 化合物4-(氯甲基)-7-羟基香豆素及其制备方法 | |
CN107043356B (zh) | 一种埃罗替尼中间体的制备方法 | |
CN103626716B (zh) | 2-(2-氨基-4-噻唑)-2(z)-[[(叔丁氧羰基)甲氧]亚氨]乙酸的制备方法 | |
CN107652230A (zh) | 一种2‑甲氧基‑7,8‑二氢喹啉‑6(5h)‑酮的合成方法 | |
CN104211890A (zh) | 一种水性聚氨酯亲水扩链剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151125 Address after: 201512 Shanghai City, Jinshan District Jinshanwei town old Weiqing Road No. 1089 Building 1 room 1159 Applicant after: Shanghai Wanxiang Pharmaceutical Co., Ltd. Applicant after: Shanghai Wonder Pharmaceutical Co., Ltd. Address before: 201518 Jinshan District Jin Zhang Road, Shanghai, No. 2068 Applicant before: Shanghai Wanxiang Pharmaceutical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161230 Address after: 200540 Shanghai city Jinshan District China Road No. 298 Patentee after: Shanghai Wanxiang Pharmaceutical Co., Ltd. Address before: 201512 Shanghai City, Jinshan District Jinshanwei town old Weiqing Road No. 1089 Building 1 room 1159 Patentee before: Shanghai Wanxiang Pharmaceutical Co., Ltd. Patentee before: Shanghai Wandai Pharmaceutical Co., Ltd. |